Melanie E Royce MD PhD

Internal Medicine•Albuquerque, NM

Hematology/Oncology

Senior Physician/Clinical Reviewer U.S. Food and Drug Administration

Join to View Full Profile

7605 Via de Calma NEAlbuquerque, NM 87113
Phone+1 505-264-2451

Summary

Dr. Melanie Royce is a medical oncologist specializing in breast cancer. She obtained her Fellowship at the The University of Texas MD Anderson Cancer Center. For over 20 years, she was in academic medicine as a practicing clinician and researcher. She is now focused on regulatory science at the USFDA with the Breast and Gynecologic Malignancies team. She has more than 70 publications and over 500 citings.

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1997 - 2000
Yale-New Haven Medical CenterResidency, Internal Medicine, 1994 - 1997
University of Cincinnati College of MedicineClass of 1994

Certifications & Licensure

TX State Medical License 1997 - 2027
NM State Medical License 2004 - 2021
CT State Medical License 1996 - 1998

Clinical Trials

Expanded Breast Cancer Registry and Tissue Repository Start of enrollment: 2006 Feb 16
Active, not recruiting
INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients Start of enrollment: 2023 Jul 31
Withdrawn
Phase 1, Phase 2
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse Start of enrollment: 2007 Nov 01
Terminated
Phase 2
Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients with Inflammatory or Invasive Breast Cancer Start of enrollment: 2007 Apr 17
RECRUITING
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
COMPLETED
PHASE2
S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer Start of enrollment: 2011 Nov 01
Completed
Not Applicable
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Start of enrollment: 2011 Jan 07
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
ACTIVE_NOT_RECRUITING
PHASE3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
ACTIVE_NOT_RECRUITING
PHASE3
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Start of enrollment: 2013 May 15
Completed
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
ACTIVE_NOT_RECRUITING
PHASE3
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. Start of enrollment: 2015 Jun 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

FDA Approval Summary: Capecitabine Labeling Update under Project Renewal.
Sundeep Agrawal, Clara Lee, William F Pierce, Elizabeth Everhart, Adriene King-Ducre
Clinical Cancer Research. 2024-12-16
4 citations
US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer.
Melanie Royce, Flora Mulkey, Christy Osgood, Erik Bloomquist, Laleh Amiri-Kordestani
Journal of Clinical Oncology. 2023-06-20
23 citations
FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer.
Melanie Royce, Christy L Osgood, Anup K Amatya, Mallorie H Fiero, C J George Chang
Clinical Cancer Research. 2022-04-14

Press Mentions

Everolimus plus Endocrine Therapy for Postmenopausal Women with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical TrialJuly 1st, 2020
Patient Selection an Important Next Step in HER2+ Breast CancerFebruary 4th, 2017
Clinical Trial Finds Concurrent Therapy Not Necessary to Achieve High Pathological in Breast CancerFebruary 10th, 2016
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Melanie E Royce MD PhD

Dr. Royce is on Doximity

Summary

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.